AI supported detection of cerebral multiple sclerosis lesions decreases radiologic reporting times

Published in

European Journal of Radiology, Vol. 178 (2024), https://doi.org/10.1016/j.ejrad.2024.111638

Authors

Peters, S., Kellermann, G., Watkinson, J., Gärtner, F., Huhndorf, M., Stürner, K., Jansen, O., Larsen, N.

Abstract

Purpose

Multiple Sclerosis (MS) is a common autoimmune disease of the central nervous system. MRI plays a crucial role in diagnosing as well as in disease and treatment monitoring. Therefore, evaluation of cerebral MRI of MS patients is part of daily clinical routine. A growing number of companies offer commercial software to support the reporting with automated lesion detection. Aim of this study was to evaluate the effect of such a software with AI supported lesion detection to the radiologic reporting.

Method

Four radiologist each counted MS-lesions in MRI examinations of 50 patients separated by the locations periventricular, cortical/juxtacortical, infrantentorial and unspecific white matter. After at least six weeks they repeated the evaluation, this time using the AI based software mdbrain for lesion detection. In both settings the required time was documented. Further the radiologists evaluated follow-up MRI of 50 MS-patients concerning new and enlarging lesions in the same manner.

Results

To determine the lesion-load the average reporting time decreased from 286.85 sec to 196.34 sec (p > 0.001). For the evaluation of the follow-up images the reporting time dropped from 196.17 sec to 120.87 sec (p < 0.001). The interrater reliabilities showed no significant differences for the determination of lesion-load (0.83 without vs. 0.8 with software support) and for the detection of new/enlarged lesions (0.92 without vs. 0.82 with software support).

Conclusion

For the evaluation of MR images of MS patients, an AI-based support for image-interpretation can significantly decreases reporting times.

Lösungen

*bald verfügbar 

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

T +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH

WELTNEUHEIT AUF DEM RÖKO 2024

Erleben Sie mdprostate, das erste vollautomatische KI-Tool für die Verlaufskontrolle in der Prostatadiagnostik.

mediaire GmbH

Möckernstrasse 63
10965 Berlin, Germany

T +49 30 286 490 67
F +49 30 286 490 66

© 2022 mediaire GmbH